Oxler Private Wealth’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-9,944
Closed -$252K 87
2025
Q1
$252K Sell
9,944
-165
-2% -$4.32K 0.09% 77
2024
Q4
$268K Sell
10,109
-402
-4% -$10.9K 0.09% 76
2024
Q3
$304K Buy
10,511
+59
+0.6% +$1.72K 0.11% 75
2024
Q2
$292K Buy
10,452
+135
+1% +$3.72K 0.11% 72
2024
Q1
$286K Sell
10,317
-148
-1% -$4.11K 0.11% 77
2023
Q4
$301K Sell
10,465
-42,927
-80% -$1.3M 0.25% 56
2023
Q3
$1.77M Sell
53,392
-7,152
-12% -$253K 0.89% 30
2023
Q2
$2.22M Buy
60,544
+633
+1% +$24.6K 1.06% 27
2023
Q1
$2.44M Buy
59,911
+35
+0.1% +$1.51K 1.21% 26
2022
Q4
$3.07M Sell
59,876
-135
-0.2% -$6.47K 1.65% 20
2022
Q3
$2.63M Buy
60,011
+500
+0.8% +$24.3K 1.47% 16
2022
Q2
$3.12M Buy
59,511
+332
+0.6% +$16.9K 1.5% 19
2022
Q1
$3.06M Buy
59,179
+505
+0.9% +$26.2K 1.38% 19
2021
Q4
$3.46M Buy
58,674
+265
+0.5% +$13.1K 1.44% 15
2021
Q3
$2.51M Sell
58,409
-166
-0.3% -$7.35K 1.11% 23
2021
Q2
$2.29M Buy
58,575
+166
+0.3% +$6.46K 1% 27
2021
Q1
$2.12M Buy
58,409
+49
+0.1% +$1.74K 1.07% 25
2020
Q4
$2.15M Buy
+58,360
New +$2.14M 1.21% 23

Other funds holding PFE

Oxler Private Wealth's PFE Position: Q2 2025 in Review

Oxler Private Wealth sold out of Pfizer (PFE) in Q2 2025, closing a stake of 9,944 shares — an estimated $252K sold.

Oxler Private Wealth first reported a position in PFE in Q4 2020 and held it in 18 quarters. The position peaked at $3.46M in Q4 2021. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

  • Oxler Private Wealth reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
  • Oxler Private Wealth sold 9,944 Pfizer shares in Q2 2025, an estimated $252K.
  • Oxler Private Wealth first reported a position in Pfizer in Q4 2020 and held it in 18 quarters.
  • Oxler Private Wealth's Pfizer position peaked at $3.46M in Q4 2021.
  • 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Oxler Private Wealth's 13F filing for Q2 2025, filed 13 Aug 2025.